Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 979-984

  Emery, P ^a,b   Gottenberg, J E ^c   Rubbert Roth, A ^d   Sarzi Puttini, P ^e   Choquette, D ^f   Martinez Taboada V M ^g   Barile Fabris, L ^h   Moots, R J ⁱ   Ostor, A ^j   Andrianakos, A ^k   Gemmen, E ^l   Mpofu, C ^m   Chung, C ⁿ   Gylvin, L Hinsch ^m   Finckh, A ^o  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k Hellenic Foundation for Rheumatological Research   (Greece)

^l IQVIA   (United States)

^m F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁿ GENENTECH INC   (United States)

^o GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; CORTICOSTEROID; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DAS28; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DRUG COMBINATION; DRUG SUBSTITUTION; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RITUXIMAB; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934914576     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203993     Document Type: Article

References (33)

1. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011;162:785-91.
2. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11(Suppl 1):S1.
3. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
4. Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007;57:448-53.
5. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
6. Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
7. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
8. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
9. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
10. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114-23.
11. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71.
12. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012;51:2252-61.
13. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8.
14. Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-278.
15. Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 2012;71:1861-4.
16. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
17. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
18. Madsen OR. Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? Clin Rheumatol 2011;30:1577-82.
19. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
20. DAS28. http://www.das28.nl/das28/en/difference-between-the-das-and-das28/how-to-measure-the-das28/how-to-calculate-the-das28.html (accessed 3 Apr 2013).
21. Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008;68:591-606.
22. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010;22:321-9.
23. Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2012;64:1108-15.
24. Finckh A, Moller B, Dudler J, et al. Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Ann Rheum Dis 2012;71:1680-5.
25. Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis - a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 2011;30:1447-54.
26. Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011;29:96-103.
27. Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012;79:281-4.
28. Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013;72:329-36.
29. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
30. Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63:933-8.
31. Klaasen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford) 2011;50:1487-93.
32. Cuchacovich M, Catalan D, Wainstein E, et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 2008;26:1067-73.
33. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.